Werewolf Therapeutics, Inc.
NASDAQ:HOWLBiotechnology
+$0.06 today
- Market cap
- $50.06M
- Beta
- 0.29
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$0.71
Volume 1.85M
Average 5.09M
HOWL Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Werewolf Therapeutics, Inc.NASDAQ: HOWL
Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Financing cash flow turns negative
Q2 FY2026 financing cash flow was -$32.41M, compared with $388K a year earlier. Trailing-twelve-month financing cash flow was -$26.77M. Over 3 fiscal years it compounded at -27.6% a year.
Context
- Financing cash flow increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly financing cash flow holds near -$32.41M or moves back toward the trailing-twelve-month quarterly average of -$6.69M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 6.03M USD
- Year-over-year change
- -53.9%
- 4-year CAGR
- -51.6%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.03M | -53.9% |
| FY2024 | 2024-12-31 | 13.08M | -77.6% |
| FY2023 | 2023-12-31 | 58.43M | +267.3% |
| FY2022 | 2022-12-31 | 15.91M | -85.5% |
| FY2021 | 2021-12-31 | 109.43M | — |
Financing Cash Flow vs competitors
How HOWL compares with its peers on the latest reported figures
- HOWL's LTM Jun 2026 financing cash flow of $26.77M is the 5th largest of the 8 companies compared; the peer median is $27.6M.
- Its year-over-year change of -1014.0% is the lowest of 8, against a peer median of +93.8%.
- Financing cash flow amounts to 127.5% of revenue for HOWL, versus a peer median of 833.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $75.28M | +53361.2% | +21.9% | — | |
| LTM Mar 2026 | $57.81M | +3300.9% | — | — | |
| LTM Mar 2026 | $47.24M | +93.8% | -8.9% | 14179.4% | |
| LTM Mar 2026 | $27.6M | +300.6% | -21.2% | 84.3% | |
| LTM Jun 2026 | $26.77M | -1014.0% | -27.6% | 127.5% | |
| LTM Mar 2026 | $22.34M | -14.0% | +235.8% | — | |
| LTM Mar 2026 | $19.12M | +27.6% | -10.3% | 833.6% | |
OSTXOS Therapies Incorporated | LTM Mar 2026 | $13.6M | +3.6% | +1272.4% | — |
| Peer median (excluding HOWL) | $27.6M | +93.8% | +6.5% | 833.6% | |
Competitors are the stored peer set for HOWL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (49.98M) | (53.81M) | (37.37M) | (70.52M) | (60.82M) |
| Depreciation & Amortization | 216K | 1.1M | 1.76M | 1.81M | 1.63M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.1M | 7.4M | 8.01M | 8.83M | 6.25M |
| Change in Working Capital | 2.28M | 2.54M | (5.89M) | 2.53M | (8.21M) |
| Accounts Receivables | 0 | (6.93M) | 5.58M | 1.35M | 0 |
| Inventory | 0 | 6.93M | 0 | 0 | 0 |
| Accounts Payables | 1.01M | (883K) | (4.34M) | 3.46M | (7.5M) |
| Other Working Capital | 1.27M | 3.42M | (7.14M) | (2.28M) | (707K) |
| Other Non-Cash Items | 519K | 2.17M | 878K | 1.16M | 856K |
| Operating Cash Flow | (42.88M) | (40.6M) | (32.61M) | (56.19M) | (60.29M) |
| Capital Expenditures | (498K) | (3.61M) | (769K) | (254K) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (498K) | (3.61M) | (769K) | (254K) | 0 |
| Debt Repayment | 0 | 0 | 40M | (10M) | 0 |
| Common Stock Issued | 111.6M | 15.74M | 18.33M | 23.58M | 6.03M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2.17M) | 166K | 100K | (496K) | 0 |
| Financing Cash Flow | 109.43M | 15.91M | 58.43M | 13.08M | 6.03M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 66.05M | (28.3M) | 25.05M | (43.36M) | (54.26M) |
| Free Cash Flow | (43.37M) | (44.21M) | (33.38M) | (56.44M) | (60.29M) |
Werewolf Therapeutics, Inc.
NASDAQ:HOWL
Intrinsic Alpha fair value
Locked
Current Price
$1.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.